TNF and Alzheimer disease: The limited effectiveness of subcutaneous anti-TNF-α therapies in AD patients may be attributed to the large molecular weight of anti-TNF-α monoclonal antibodies because this makes the passage through the blood–brain barrier impossible under physiological conditions [82].